Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial

Circulation

Volumn 97, Issue 4, 1998, Pages 340-349

  Cannon, Christopher P ^a   McCabe, Carolyn H ^a   Borzak, Steven ^b   Henry, Timothy D ^c   Tischler, Marc D ⁱ   Mueller, Hiltrud S ^d   Feldman, Robert ^e   Palmeri, Sebastian T ^f   Ault, Kenneth ⁱ   Hamilton, Scott A ^g   Rothman, Joel M ^g   Novotny, William F ^g   Braunwald, Eugene ^a,h  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e Munroe Regional Med Center   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g GENENTECH INC   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ NONE

Author keywords

Angina; Aspirin; Myocardial infarction; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; SIBRAFIBAN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0032477680     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.4.340     Document Type: Article

References (29)

1. Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley KM, Edwards C, Green LA, Mushlin AI, Swain JA, Smith EE III, Cowan M, Rose GC, Concannon CA, Grines CL, Brown L, Lytle BW, Goldman L, Topol EJ, Willerson JT, Brown J, Archibald N. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10, Rockville. Md: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, US Department of Health and Human Services; 1994.
2. Antiplatelet Trialist' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
3. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk angioplasty. N Engl J Med. 1994;330:956-961.
4. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Signom K, Anderson KM, Lee KL, Willerson JT, for the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
5. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
6. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gertenblith G. Effects of Integrelin, a platelet glycoprotein IIb/IIIa antagonist, in unstable angina: a randomized multicenter trial. Circulation. 1996;94:2083-2089.
7. Theroux P, White H, David D, Van de Werf F, Nienaber CA, Charbonnier B, Erhardt L, Gill J, Hillis WS, Jennings G, Tan L-B, Deschenes N, Ritzpatrick V, Sax FL. A heparin-controlled study of MK-383 in unstable angina. Circulation 1994;90(pt 2):I-231. Abstract.
8. Theroux P. Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms. Presented at the American College of Cardiology Scientific Sessions; 1997; Anaheim, Calif.
9. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349:1422-1428.
10. The RESTORE Investigators. The effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
11. Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadvary P, Muller MH, Knopp D, Lever-Trafit B, Lipari MT, Modi NB, Muller M, Refino CJ, Schmitt M, Schonholzer P, Weiss S, Steiner B. Orally active fibrinogen receptro antagonists, 2: amidoximes as prodrugs of amidines. J Med Chem. 1996;39:3139-3147.
12. Kleiman N, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasry in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol. 1993;22:381-389.
13. Sabo T, Gurwitz D, Motola L, Brodt P, Barak R, Elhanaty E. Structure-activity studies of the thrombin receptor activating peptide. Biochem Biophys Res Commun. 1992;188:604-610.
14. Connolly TM, Condra C, Feng DM, Cook JJ, Stranieri MT, Reilly CF, Nutt RF, Gould RJ. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost. 1994;72:627-633.
15. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robenson T, Ross A, Ryan TJ, Sobel B, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142-154.
16. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore J, Hillis D, Lambrew CT, Leigoff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH, for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial. Ann Intern Med. 1991;115:256-265.
17. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
18. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mee CP, Califf RM, Topol EJ. Multi-center, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation. 1995;91:2151-2157.
19. Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab: administration for complex coronary intervention. Circulation. 1996;94:906-910.
20. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquid J-F, Nasmith J, Fung AY, Boudreault J-R, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ, for the Canadian Lamifiban Study Investigators. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban Study. Circulation. 1996;94:899-905.
21. PARAGON Investigators. A randomized trial of potent platelet IIb/IIIa antagonism, heparin, or both in patients with unstable angina: the PARAGON study. Circulation. 1996;94(suppl I):I-553. Abstract.
22. Harrington RA, Newby LK, Moliterno DJ, Bhapkar M, Armstrong P, Simes RJ, White HD, Van de Werf F, Rames A, Topol EJ, Califf RM, for the PARAGON Investigators. Combining IIb/IIIa inhibition and heparin for acute coronary syndromes: evidence of a gradient for bleeding hazard from the PARAGON randomized factorially designed trial. J Am Coll Cardiol. 1997;29(suppl A):410A. Abstract.
23. Cannon CP, Becker RC, Loscalzo J, Gallo P, Henis M, Edwards SJ, McCabe CH, Braunwald E, for the TIMI 5 Investigators. Usefulness of APTT to predict bleeding for hirudin (and heparin). Circulation. 1994;90(pt 2):I-563. Abstract.
24. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes J, Topol EJ, for the GUSTO-I Investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996;93:870-878.
25. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5-10.
26. Cannegieter SC, Rosendaal RF, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E. Optimal oral anticoagulation therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11-17.
27. George JN, Caen JP, Nurden AT. Glansmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990;75:1383-1395.
28. Konstantinos K, Kamat SG, Schafer AI, Banez EI, Jordan R, Kleiman NS, Hellms D. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patient undergoing coronary angioplasty. Circulation. 1995;91:1427-1431.
29. Coller BS, Land D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation. 1997;95:860-867.